Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly

In this article

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

GLP-1 pills for obesity are closer than ever.

2026 is likely the year that two new oral weight loss drugs will reach patients in the U.S. For some people, pills may serve as a more convenient – and potentially in certain cases cheaper – alternative to today’s blockbuster injections.

Drugmakers Novo Nordis

Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly

Related reading

2026 is the year of obesity pills. Here's how they could reshape the GLP-1…

Healthy Returns: Novo Nordisk boosts the case for its upcoming obesity pill…

Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug…

What obesity drugmakers see next in the market: More pills, easier access and…

GLP-1s could end up being ‘the first true longevity drug’ as the world battles…

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk